1
|
Slak Rupnik M, Hara M. Local Dialogues Between the Endocrine and Exocrine Cells in the Pancreas. Diabetes 2024; 73:533-541. [PMID: 38215069 PMCID: PMC10958587 DOI: 10.2337/db23-0760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Accepted: 01/03/2024] [Indexed: 01/14/2024]
Abstract
For many years, it has been taught in medical textbooks that the endocrine and exocrine parts of the pancreas have separate blood supplies that do not mix. Therefore, they have been studied by different scientific communities, and patients with pancreatic disorders are treated by physicians in different medical disciplines, where endocrine and exocrine function are the focus of endocrinologists and gastroenterologists, respectively. The conventional model that every islet in each pancreatic lobule receives a dedicated arterial blood supply was first proposed in 1932, and it has been inherited to date. Recently, in vivo intravital recording of red blood cell flow in mouse islets as well as in situ structural analysis of 3D pancreatic vasculature from hundreds of islets provided evidence for preferentially integrated pancreatic blood flow in six mammalian species. The majority of islets have no association with the arteriole, and there is bidirectional blood exchange between the two segments. Such vascularization may allow an entire downstream region of islets and acinar cells to be simultaneously exposed to a topologically and temporally specific plasma content, which could underlie an adaptive sensory function as well as common pathogeneses of both portions of the organ in pancreatic diseases, including diabetes. ARTICLE HIGHLIGHTS
Collapse
Affiliation(s)
- Marjan Slak Rupnik
- Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria
| | - Manami Hara
- Department of Medicine, The University of Chicago, Chicago, IL
| |
Collapse
|
2
|
Hagelkruys A, Wirnsberger G, Stadlmann J, Wöhner M, Horrer M, Vilagos B, Jonsson G, Kogler M, Tortola L, Novatchkova M, Bönelt P, Hoffmann D, Koglgruber R, Steffen U, Schett G, Busslinger M, Bergthaler A, Klein C, Penninger JM. A crucial role for Jagunal homolog 1 in humoral immunity and antibody glycosylation in mice and humans. J Exp Med 2021; 218:e20200559. [PMID: 32930709 PMCID: PMC7953624 DOI: 10.1084/jem.20200559] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2020] [Revised: 07/17/2020] [Accepted: 08/18/2020] [Indexed: 12/28/2022] Open
Abstract
Jagunal homolog 1 (JAGN1) has been identified as a critical regulator of neutrophil biology in mutant mice and rare-disease patients carrying JAGN1 mutations. Here, we report that Jagn1 deficiency results in alterations in the endoplasmic reticulum (ER) of antibody-producing cells as well as decreased antibody production and secretion. Consequently, mice lacking Jagn1 in B cells exhibit reduced serum immunoglobulin (Ig) levels at steady state and fail to mount an efficient humoral immune response upon immunization with specific antigens or when challenged with viral infections. We also demonstrate that Jagn1 deficiency in B cells results in aberrant IgG N-glycosylation leading to enhanced Fc receptor binding. Jagn1 deficiency in particular affects fucosylation of IgG subtypes in mice as well as rare-disease patients with loss-of-function mutations in JAGN1. Moreover, we show that ER stress affects antibody glycosylation. Our data uncover a novel and key role for JAGN1 and ER stress in antibody glycosylation and humoral immunity in mice and humans.
Collapse
Affiliation(s)
- Astrid Hagelkruys
- Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria
| | - Gerald Wirnsberger
- Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria
- Apeiron Biologics AG, Vienna, Austria
| | - Johannes Stadlmann
- Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria
- Institute of Biochemistry, University of Natural Resource and Life Sciences, Vienna, Austria
| | - Miriam Wöhner
- Research Institute of Molecular Pathology, Vienna Biocenter, Vienna, Austria
| | - Marion Horrer
- Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria
| | - Bojan Vilagos
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
| | - Gustav Jonsson
- Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria
| | - Melanie Kogler
- Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria
| | - Luigi Tortola
- Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria
- Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland
| | - Maria Novatchkova
- Research Institute of Molecular Pathology, Vienna Biocenter, Vienna, Austria
| | - Peter Bönelt
- Research Institute of Molecular Pathology, Vienna Biocenter, Vienna, Austria
| | - David Hoffmann
- Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria
| | - Rubina Koglgruber
- Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria
| | - Ulrike Steffen
- Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
| | - Georg Schett
- Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
| | - Meinrad Busslinger
- Research Institute of Molecular Pathology, Vienna Biocenter, Vienna, Austria
| | - Andreas Bergthaler
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
| | - Christoph Klein
- Department of Pediatrics, Dr. von Hauner Children’s Hospital, Ludwig Maximilians University, Munich, Germany
| | - Josef M. Penninger
- Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria
- Department of Medical Genetics, Life Science Institute, University of British Columbia, Vancouver, Canada
| |
Collapse
|
3
|
Kargas V, Castro-Hartmann P, Escudero-Urquijo N, Dent K, Hilcenko C, Sailer C, Zisser G, Marques-Carvalho MJ, Pellegrino S, Wawiórka L, Freund SMV, Wagstaff JL, Andreeva A, Faille A, Chen E, Stengel F, Bergler H, Warren AJ. Mechanism of completion of peptidyltransferase centre assembly in eukaryotes. eLife 2019; 8:e44904. [PMID: 31115337 PMCID: PMC6579518 DOI: 10.7554/elife.44904] [Citation(s) in RCA: 38] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2019] [Accepted: 05/20/2019] [Indexed: 01/05/2023] Open
Abstract
During their final maturation in the cytoplasm, pre-60S ribosomal particles are converted to translation-competent large ribosomal subunits. Here, we present the mechanism of peptidyltransferase centre (PTC) completion that explains how integration of the last ribosomal proteins is coupled to release of the nuclear export adaptor Nmd3. Single-particle cryo-EM reveals that eL40 recruitment stabilises helix 89 to form the uL16 binding site. The loading of uL16 unhooks helix 38 from Nmd3 to adopt its mature conformation. In turn, partial retraction of the L1 stalk is coupled to a conformational switch in Nmd3 that allows the uL16 P-site loop to fully accommodate into the PTC where it competes with Nmd3 for an overlapping binding site (base A2971). Our data reveal how the central functional site of the ribosome is sculpted and suggest how the formation of translation-competent 60S subunits is disrupted in leukaemia-associated ribosomopathies.
Collapse
Affiliation(s)
- Vasileios Kargas
- Cambridge Institute for Medical ResearchCambridgeUnited Kingdom
- Department of HaematologyUniversity of CambridgeCambridgeUnited Kingdom
- Wellcome Trust–Medical Research Council Stem Cell InstituteUniversity of CambridgeCambridgeUnited Kingdom
| | - Pablo Castro-Hartmann
- Cambridge Institute for Medical ResearchCambridgeUnited Kingdom
- Department of HaematologyUniversity of CambridgeCambridgeUnited Kingdom
- Wellcome Trust–Medical Research Council Stem Cell InstituteUniversity of CambridgeCambridgeUnited Kingdom
| | - Norberto Escudero-Urquijo
- Cambridge Institute for Medical ResearchCambridgeUnited Kingdom
- Department of HaematologyUniversity of CambridgeCambridgeUnited Kingdom
- Wellcome Trust–Medical Research Council Stem Cell InstituteUniversity of CambridgeCambridgeUnited Kingdom
| | - Kyle Dent
- Cambridge Institute for Medical ResearchCambridgeUnited Kingdom
- Department of HaematologyUniversity of CambridgeCambridgeUnited Kingdom
- Wellcome Trust–Medical Research Council Stem Cell InstituteUniversity of CambridgeCambridgeUnited Kingdom
| | - Christine Hilcenko
- Cambridge Institute for Medical ResearchCambridgeUnited Kingdom
- Department of HaematologyUniversity of CambridgeCambridgeUnited Kingdom
- Wellcome Trust–Medical Research Council Stem Cell InstituteUniversity of CambridgeCambridgeUnited Kingdom
| | - Carolin Sailer
- Department of BiologyUniversity of KonstanzKonstanzGermany
| | - Gertrude Zisser
- Institute of Molecular BiosciencesUniversity of GrazGrazAustria
| | - Maria J Marques-Carvalho
- Cambridge Institute for Medical ResearchCambridgeUnited Kingdom
- Department of HaematologyUniversity of CambridgeCambridgeUnited Kingdom
- Wellcome Trust–Medical Research Council Stem Cell InstituteUniversity of CambridgeCambridgeUnited Kingdom
| | - Simone Pellegrino
- Cambridge Institute for Medical ResearchCambridgeUnited Kingdom
- Department of HaematologyUniversity of CambridgeCambridgeUnited Kingdom
- Wellcome Trust–Medical Research Council Stem Cell InstituteUniversity of CambridgeCambridgeUnited Kingdom
| | - Leszek Wawiórka
- Cambridge Institute for Medical ResearchCambridgeUnited Kingdom
- Department of HaematologyUniversity of CambridgeCambridgeUnited Kingdom
- Wellcome Trust–Medical Research Council Stem Cell InstituteUniversity of CambridgeCambridgeUnited Kingdom
- Department of Molecular BiologyMaria Curie-Skłodowska UniversityLublinPoland
| | | | | | | | - Alexandre Faille
- Cambridge Institute for Medical ResearchCambridgeUnited Kingdom
- Department of HaematologyUniversity of CambridgeCambridgeUnited Kingdom
- Wellcome Trust–Medical Research Council Stem Cell InstituteUniversity of CambridgeCambridgeUnited Kingdom
| | - Edwin Chen
- Faculty of Biological SciencesUniversity of LeedsLeedsUnited Kingdom
| | | | - Helmut Bergler
- Institute of Molecular BiosciencesUniversity of GrazGrazAustria
| | - Alan John Warren
- Cambridge Institute for Medical ResearchCambridgeUnited Kingdom
- Department of HaematologyUniversity of CambridgeCambridgeUnited Kingdom
- Wellcome Trust–Medical Research Council Stem Cell InstituteUniversity of CambridgeCambridgeUnited Kingdom
| |
Collapse
|